By Richard Staines, Optimum Strategic Communications The re-election of Donald Trump as President of the Unites States represents a seismic shift in the U.S. political system, with huge ramifications for all policy areas including healthcare. But, at the time of writing, the identity of the next Secretary of the Department of Health and Human Services […]
LONDON, Oct. 8, 2024 /PRNewswire/ — Optimum Strategic Communications (Optimum), the international strategic healthcare communications consultancy, will be hosting its 16th Annual Healthcare Investor Conference on Thursday 10 October, 2024 at The Kings Fund, London. This year, as markets begin to bounce back after a lacklustre period, a prestigious line-up of industry experts will look to growth, identifying which therapies will attract investor […]
Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine Vicebio Ltd, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, on Monday announced a $100 million Series B financing led by TCGX with investment from Goldman Sachs Alternatives, Avoro Ventures, venBio, and participation from UniQuest and founding investor Medicxi. London-based Vicebio said funding […]
The death cap mushroom is feared throughout much of the world because of the deadly toxin it contains, amanitin. But could the poison reputedly used by Agrippina to murder her husband, the Roman emperor Claudius, be used to destroy cancer, asks Richard Staines. Known to modern science as an inhibitor of RNA polymerase II, alpha-Amanitin […]
AstraZeneca buys Novo Holdings portfolio company Amolyt in potential $1bn+ deal Novo Holdings A/S and Sofinnova Partners, two leading life sciences investors, made headlines on Thursday when portfolio company Amolyt Pharma entered into a definitive agreement to be acquired by AstraZeneca at a purchase price of US$800 million upfront and a potential milestone payment of […]
